


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound according to the general Formula (I)



the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the *N*-oxide form thereof, wherein:

X is CH₂, N-R⁷, S or O ;

R⁷ is selected from the group consisting of hydrogen, alkyl, Ar, Ar-alkyl, alkylcarbonyl, alkyloxy carbonyl and mono- and di(alkyl)aminocarbonyl;


R¹ and R² are each selected from the group consisting of hydrogen, halo, hydroxy, -OSO₂H, -OSO₂CH₃, alkyloxy, alkyloxyalkyloxy, alkyloxyalkyloxyalkyloxy, tetrahydrofuranyloxy, alkylcarbonyloxy, alkyloxyalkylcarbonyloxy, pyridinylcarbonyloxy, alkylcarbonyloxyalkyloxy, alkyloxy carbonyloxy, alkenyloxy, alkenylcarbonyloxy, mono- or di(alkyl)aminoalkyloxy, -N-R¹⁰R¹¹, alkylthio, Alk, Ar and Het,

with the proviso that at least one of R¹ and R² is selected from the group consisting of Alk, Ar and Het, wherein

Alk is cyano, CN-OH, CN-oxyalkyl, alkyl, alkyloxyalkyl, alkyloxyalkyloxyalkyl, alkyloxyalkyloxyalkyloxyalkyl, alkylcarbonylalkyl, alkylcarbonyloxyalkyl, alkyloxy carbonylalkyl, Ar-alkyl, Ar-carbonylalkyl, Ar-oxyalkyl, mono- or di(alkyl)aminoalkyl, mono- or di(alkylcarbonyl)aminoalkyl, mono- or di(alkyl)aminocarbonylalkyl,

- Het-alkyl, formyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkylcarbonyl, mono- or di(alkyl)aminocarbonyl, Ar-carbonyl and Ar-oxycarbonyl ;
- Ar is phenyl or naphthyl, optionally substituted with one or more halo, cyano, oxo, hydroxy, alkyl, formyl, alkyloxy or amino radicals.
- Het is a heterocyclic radical selected from the group consisting of Het¹, Het² and Het³ ;
- Het¹ is an aliphatic monocyclic heterocyclic radical selected from the group consisting of pyrrolidinyl, dioxolyl, imidazolidinyl, pyrrazolidinyl, piperidinyl, dioxyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl and tetrahydrofuryl ;
- Het² is a semi-aromatic monocyclic heterocyclic radical selected from the group consisting of 2H-pyrrolyl, pyrrolinyl, imidazolinyl and pyrrazolinyl ;
- Het³ is an aromatic monocyclic heterocyclic radical selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl and triazinyl; or an aromatic bicyclic heterocyclic radical selected from the group consisting of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothienyl ;
- wherein each Het¹, Het² and Het³-radical may optionally be substituted on either a carbon or heteroatom with halo, hydroxy, alkyloxy, alkyl, Ar, Ar-alkyl, formyl, alkylcarbonyl or pyridinyl ;
- R¹⁰ and R¹¹ are each, independently from each other, selected from the group consisting of hydrogen, alkyl, Ar, Ar-alkyl, pyrrolidinylalkyl, piperidinylalkyl, homopiperidinylalkyl, piperazinylalkyl, morpholinylalkyl, mono- or di(alkyl)aminoalkyl, alkylcarbonyl, alkenylcarbonyl, Ar-carbonyl, pyridinylcarbonyl, alkyloxycarbonyl, mono- or di(alkyl)aminocarbonyl, mono- or di(Ar)aminocarbonyl, mono- or di(alkyloxycarbonylalkyl)aminocarbonyl, pyrrolidinylcarbonyl, aminoiminomethyl, alkylaminoiminomethyl, N-

benzylpiperazinyliminomethyl, alkylsulphonyl and Ar-sulphonyl ; or
 R^{10} and R^{11} may be taken together and with the N may form a monovalent radical
 selected from the group of



wherein :

R^{12} is selected from the group consisting of hydrogen, alkyl, Ar, Ar-alkyl, Ar-alkenyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkylcarbonyl and mono- or di(alkyl)aminocarbonyl ;


each ring being optionally substituted with q radicals R^{13} , each radical independently from each other selected from the group of alkyl, oxo, Ar, Ar-alkyl, Ar-alkenyl and alkyloxycarbonyl and q being an integer ranging from 0 to 6 ; or

R^1 and R^2 may be taken together to form a bivalent radical $-R^1-R^2-$ selected from the group consisting of $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-\text{CH}=\text{CH}-$, $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-$ and $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$;

a and b are asymmetric centers ;

$(\text{CH}_2)_m$ is a straight hydrocarbon chain of m carbon atoms, m being an integer ranging from 1 to 4 ;

Pir is a radical according to any one of Formula (IIa), (IIb) or (IIc)



optionally substituted with n radicals R^8 , wherein :

each R^8 is independently from each other, selected from the group consisting of hydroxy, amino, nitro, cyano, halo and alkyl ;

n is an integer ranging from 0 to 5 ;

R^9 is selected from the group consisting of hydrogen, alkyl and formyl;


R^3 represents an optionally substituted aromatic homocyclic or heterocyclic ring system together with an optionally substituted and partially or completely hydrogenated hydrocarbon chain of 1 to 6 atoms long with which said ring system is attached to the Pir radical and of which may contain one or more heteroatoms selected from the group of O, N and S ;

alkyl represents a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, optionally substituted with one or more halo, cyano, oxo, hydroxy, formyl or amino radicals ;

alkenyl represents a straight or branched unsaturated hydrocarbon radical having one or more double bonds, optionally substituted with one or more halo, cyano, oxo, hydroxy, formyl or amino radicals ; and

halo is fluoro, chloro, bromo and iodo.

2. (Currently Amended) A compound according to claim 1, characterized in that R^3 is a radical according to any one of Formula (IIIa), (IIIb) or (IIIc)



wherein :

d is a single bond while Z is a bivalent radical selected from the group consisting of $-\text{CH}_2-$, $-\text{C}(=\text{O})-$, $-\text{CH}(\text{OH})-$, $-\text{C}(=\text{N}-\text{OH})-$, $-\text{CH}(\text{alkyl})-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(=\text{O})-$, $-\text{NH}-$ and $-\text{SH}-$; or d is a double bond while Z is a trivalent radical of formula $=\text{CH}-$ or $=\text{C}(\text{alkyl})-$;

A is a 5- or 6-membered aromatic homocyclic or heterocyclic ring, selected from the group consisting of phenyl, pyranyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, oxadiazolyl and isoxazolyl ;

p is an integer ranging from 0 to 6 ;

R^4 and R^5 are each, independently from each other, selected from the group consisting of hydrogen, alkyl, Ar, biphenyl, halo and cyano ; or

R^4 and R^5 may be taken together to form a bivalent radical $-\text{R}^4-\text{R}^5-$ selected from the group consisting of $-\text{CH}_2-$, $=\text{CH}-$, $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{O}-$, $-\text{NH}-$, $=\text{N}-$, $-\text{S}-$, $-\text{CH}_2\text{N}(-\text{alkyl})-$, $-\text{N}(-\text{alkyl})\text{CH}_2-$, $-\text{CH}_2\text{NH}-$, $-\text{NHCH}_2-$, $-\text{CH}=\text{N}-$, $-\text{N}=\text{CH}-$, $-\text{CH}_2\text{O}-$ and $-\text{OCH}_2-$;

each R^6 is independently from each other, selected from the group consisting of hydroxy, amino, nitro, cyano, halo, carboxyl, alkyl, Ar, alkyloxy, Ar-oxy, alkylcarbonyloxy, alkyloxycarbonyl, alkylthio, mono- and di(alkyl)amino, alkylcarbonylamino, mono- and di(alkyl)aminocarbonyl, mono- and di(alkyl)aminocarbonyloxy, mono- and

di(alkyl)aminoalkyloxy ; or

two vicinal radicals R^6 may be taken together to form a bivalent radical $-R^6-R^6-$

selected from the group consisting of $-CH_2-CH_2-O-$, $-O-CH_2-CH_2-$, $-O-CH_2-C(=O)-$,

$-C(=O)-CH_2-O-$, $-O-CH_2-O-$, $-CH_2-O-CH_2-$, $-O-CH_2-CH_2-O-$, $-CH=CH-CH=CH-$,

$-CH=CH-CH=N-$, $-CH=CH-N=CH-$, $-CH=N-CH=CH-$, $-N=CH-CH=CH-$, $-CH_2-CH_2-$

CH_2- , $-CH_2-CH_2-C(=O)-$, $-C(=O)-CH_2-CH_2-$, $-CH_2-C(=O)-CH_2-$ and

$—CH_2-CH_2-CH_2-CH_2-$ and

R^{16} is selected from the group consisting of hydrogen, alkyl, Ar and Ar-alkyl.

3. (Currently Amended) A compound according to claim 2, wherein ~~characterized in that~~ $X=O$; $m = 1$; Pir is a radical according to Formula (IIa) wherein $n = 0$; R^3 is a radical according to Formula (IIIb) wherein d is a double bond while Z is a trivalent radical of formula $=CH-$, A is a phenyl ring, R^4 is hydrogen or alkyl, R^5 and R^{16} are each hydrogen, R^6 is hydrogen or halo and

$p = 1$.

4. (Currently Amended) A compound according to claim 1, ~~wherein any one of claims 1 to 3, characterized in that~~ at least one of R^1 and R^2 is selected from the group consisting of cyano optionally substituted with hydroxy or alkyloxy ; alkyl ; hydroxyalkyl ; aminoalkyl ; alkyloxyalkyl ; alkyloxyalkyloxyalkyloxyalkyl ; alkylcarbonyloxyalkyl ; Ar-oxyalkyl ; mono- or di(alkyl)aminoalkyl, the alkyl radicals optionally substituted with hydroxy ; mono- or di(alkylcarbonyl)aminoalkyl ; mono- or di(alkyl)aminocarbonyl ; piperidinylalkyl ; morpholinylalkyl ; phenyl and thienyl optionally substituted with alkylcarbonyl.

5. (Currently Amended) A compound according to claim 1 ~~any one of claims 1 to 4 with the following name:~~ selected from the group consisting of:

- 8-Methyl-3-[4-(3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole (~~compound 1~~) ;
- 8-Methoxy-7-methyl-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole (~~compound 2~~);

- {8-Methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazol-7-yl}-methanol (~~compound 4~~);
- 7-Methoxymethyl-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazole (~~compound 5~~);
- 8-Methoxy-7-(2-methoxy-ethoxymethoxymethyl)-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazole (~~compound 6~~) ;
- Acetic acid 8-methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazol-7-ylmethyl ester (~~compound 7~~) ;
- 8-Methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-7-phenoxyethyl-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazole (~~compound 8~~) ;
- 2-(Methyl-{3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazol-7-ylmethyl}-amino)-ethanol (~~compound 9~~) ;
- 8-Methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-7-morpholin-4-ylmethyl-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazole (~~compound 10~~);
- 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazole-7-carbaldehyde oxime (~~compound 11~~);
- 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazole-7-carbaldehyde O-methyl-oxime (~~compound 12~~);
- 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazole-7-carbonitrile (~~compound 13~~);
- *N*-(3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazol-7-ylmethyl)-acetamide (~~compound 14~~) ;
- 8-Methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazole-7-carboxylic acid ethylamide (~~compound 15~~) ;
- 8-Methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-7-phenyl-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazole (~~compound 16~~) ; and
- 1-(5-{8-Methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3*H*-chromeno[4,3-*c*]isoxazol-7-yl}-thiophen-2-yl)-ethanone (~~compound 17~~).

6. (Currently Amended) A compound which is degraded *in vivo* to yield a compound according to claim 1 ~~any one of claims 1 to 5~~.
7. (Currently Amended) A compound according to claim 1 ~~any one of claims 1 to 6~~ for use as a medicine.
8. (Currently Amended) A method ~~The use of a compound according to any one of claims 1 to 7 for the manufacture of a medicament~~ for the treatment and/or prophylaxis of depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders comprising administering a therapeutically effective amount of the compound of claim 1.
9. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient a therapeutically effective amount of a compound according to claim 1 ~~any one of claims 1 to 7~~.
10. (Currently Amended) A process for making a pharmaceutical composition ~~according to claim 9~~, comprising mixing a compound according to claim 1 ~~any one of claims 1 to 7~~ and a pharmaceutically acceptable carrier.
11. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient a therapeutically effective amount of a compound according to claim 1 ~~any one of claims 1 to 7~~ and one or more other compounds selected from the group consisting of antidepressants, anxiolytics and antipsychotics and anti-Parkinson's disease drugs .
12. (Canceled)
13. (Currently Amended) A method ~~The use of a compound according to any one of claims 1 to 7 for the manufacture of a medicament~~ for the treatment and/or prophylaxis of

depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders, said treatment comprising the simultaneous or sequential administration of a therapeutically effective amount of compound according to claim 1 ~~any one of claims 1-7~~ and one or more other compounds selected from the group consisting of antidepressants, anxiolytics, anti-psychosis and anti-Parkinson's drugs.

14. (Currently Amended) The method of claim 13 wherein the ~~use of one or more compounds selected from the group of antidepressants, anxiolytics and antipsychotics for the manufacture of a medicament for~~ the treatment and/or prophylaxis is for of depression, anxiety and body weight disorders, said treatment comprising the simultaneous or sequential administration of one or more compounds selected from the group consisting of antidepressants, anxiolytics and antipsychotics and anti-Parkinson's disease drugs and a compound according to claim 1. ~~any one of claims 1 to 7.~~

15. (Currently Amended) A process for making a pharmaceutical composition ~~The use of a pharmaceutical composition according to claim 11~~ to improve efficacy and/or onset of action in the treatment and/or prophylaxis of depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders comprising mixing a pharmaceutical excipient, a therapeutically effective amount of one or more compounds selected from the group consisting of antidepressants, anxiolytics and antipsychotics and anti-Parkinson's disease drugs and a compound according to claim 1.

16. (Currently Amended) A process for making a pharmaceutical composition ~~according to claim 11~~, comprising mixing a compound according to claim 1 ~~any one of claims 1 to 7~~ and a compound selected from the group consisting of antidepressants, anxiolytics, antipsychotics and anti-Parkinson's disease drugs and a pharmaceutically acceptable carrier.